Aqueous Extract of Paeonia suffruticosa Inhibits Migration and Metastasis of Renal Cell Carcinoma Cells via Suppressing VEGFR-3 Pathway by Wang, Shih-Chin et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 409823, 9 pages
doi:10.1155/2012/409823
Research Article
AqueousExtract of Paeoniasuffruticosa Inhibits
Migration andMetastasis of RenalCellCarcinoma Cellsvia
SuppressingVEGFR-3 Pathway
Shih-Chin Wang,1 Sai-Wen Tang,1 Sio-Hong Lam,2 Chung-Chieh Wang,3 Yu-Huei Liu,1,4,5
Hsuan-YuanLin,1 Shoei-ShengLee,2 andJung-YawLin1
1Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
2School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
3Department of Pathology, National Taiwan University Hospital, Taipei 10002, Taiwan
4Graduate Institute of Integrated Medicine of Chinese Medicine, China Medical University, Taichung, Taiwan
5Department of Medical Genetics and Medical Research, China Medical University Hospital, Taichung, Taiwan
Correspondence should be addressed to Jung-Yaw Lin, linjy@ntu.edu.tw
Received 28 June 2011; Accepted 2 November 2011
Academic Editor: Lixing Lao
Copyright © 2012 Shih-Chin Wang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Renalcellcarcinoma(RCC)cellsarecharacterizedbystrongdrugresistanceandhighmetastaticincidence.Inthisstudy,theeﬀects
of ten kinds of Chinese herbs on RCC cell migration and proliferation were examined. Aqueous extract of Paeonia suﬀruticosa(PS-
A) exerted strong inhibitory eﬀects on cancer cell migration, mobility, and invasion. The results of mouse xenograft experiments
showed that the treatment of PS-A signiﬁcantly suppressed tumor growth and pulmonary metastasis. We further found that PS-A
markedlydecreasedexpressionofVEGFreceptor-3(VEGFR-3)andphosphorylationofFAKinRCCcells.Moreover,theactivation
of Rac-1, a modulator of cytoskeletal dynamics, was remarkably reduced by PS-A. Additionally, PS-A suppressed polymerization
of actin ﬁlament as demonstrated by confocal microscopy analysis and decreased the ratio of F-actin to G-actin in RCC cells,
suggesting that PS-A inhibits RCC cell migration through modulating VEGFR-3/FAK/Rac-1 pathway to disrupt actin ﬁlament
polymerization. In conclusion, this research elucidates the eﬀects and molecular mechanism for antimigration of PS-A on RCC
cells and suggests PS-A to be a therapeutic or adjuvant strategy for the patients with aggressive RCC.
1.Introduction
Chinese herb medicines have been discovered to be potential
therapies for various diseases, including diabetes mellitus,
tumor, and hypertension [1]. Recently, increasing evidence
has shown that some of Chinese herb medicines can be
applied to improve the eﬃciency of conventional cancer
therapies and reduce the side eﬀects of chemotherapies for
human malignancies, such as breast cancer and prostate
cancer [2, 3].
The root cortex of Paeonia suﬀruticosa has been widely
used as traditional Chinese herb remedy for treating various
diseases, including macula, epilepsy, and menstrual disor-
ders [4]. Paeonia suﬀruticosa was demonstrated to exhibit
antiproliferation, anti-inﬂammation, antiinfection, antihy-
pertention, antidiabetics, and neuroprotective activities [5–
8]. The active compounds have been identiﬁed from Paeonia
suﬀruticosa, such as paeonol and paeoniﬂorin [9–14]. How-
ever, the eﬀect and detailed mechanism for antimigration of
Paeonia suﬀruticosa on cancer cells are still unclear.
Renal cell carcinoma (RCC) represents 3% of all human
malignancies worldwide with an increasing incidence [15–
17]. About 70% of RCCs have been found to be clear
cell subtype [18]. The response of RCC cells to traditional
therapies, such as the chemotherapy, hormonal therapy, and
radiation therapy is very poor [19, 20], and one-fourth of
the patients have locally invasive or metastatic RCC [21, 22],
resulting in a low ﬁve-year survival rate of RCC patients.2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Chemical proﬁle of PS-A by HPLC analysis. Chromato-
graphic patterns of PS-A from HPLC analysis (230nm) showed
peaks corresponding to the retention times (min). Paeoniﬂorin (1)
and paeonol (2) were used as reference compounds for Paeonia
suﬀruticosa.
Several immunotherapies have been used for the treatment
ofmetastaticRCC[23],butonlysmallpopulationofpatients
with advanced RCC show response with a high toxicity [24].
In this study, we examined the antimigration and
antiproliferation eﬀects of the aqueous extracts from ten
kinds of Chinese herb medicines, including Paeonia suﬀruti-
cosa, Trichosanthes kirilowii, San jhong kuei jian tang, Tarax-
acum monogolicum, Kalimeris indica, Platycodi radix, Abrus
precatorius, Catharanthus roseus, Andrographis paniculata,
and Curcuma zedoaria, and further elucidated the molecular
mechanism for the strong antimigration activity of Paeonia
suﬀruticosa to RCC cells.
2.MaterialsandMethods
2.1. Preparation of Chinese Herb Extracts. Aqueous extracts
from Paeonia suﬀruticosa, Trichosanthes kirilowii, San jhong
kuei jian tang, Taraxacum monogolicum, Kalimeris indica, Pl-
atycodi Radix, Abrus precatorius, Catharanthus roseus, Andro-
graphis paniculata, and Curcuma zedoaria were provided by
Sun-Ten Pharmaceutical Company (Taipei, Taiwan). Brieﬂy,
one hundred grams of dried Chinese herbs was boiled
with 1,500mL of H2O at 100◦C for 30min and was sieved
using a 100-mesh sieve. The extracts were concentrated to
100mL and were ﬁltered through a 200-mesh sieve. The ex-
tracts were dried by speed vacuum concentration and then
stored at −20◦C until used. Furthermore, the chemical
proﬁle of aqueous extracts of Paeonia suﬀruticosa (PS-A)
was analyzed by using high-pressure liquid chromatograms
(HPLC) and shown in Figure 1. Brieﬂy, HPLC was per-
formed using an Agilent 1100 liquid chromatography
(Waldbronn, Germany), consisting of a photodiode array
detector. The chromatographic separation of samples (20μL,
20mg/mL) was carried out on a Phenomenex Prodigy
ODS3 100A column (250 × 4.6mm, 5μm), eluted with the
mixtureofwater(A)andacetonitrile(B).Thelineargradient
program was set as A-B (v/v) from 90:10 to 5:95 in 60min
with a ﬂow rate of 0.6mL/min. Absorbance was monitored
at 230nm. Paeoniﬂorin and paeonol were used as reference
compounds for Paeonia suﬀruticosa [10].
2.2. Chemicals and Reagents. Paeonol was purchased from
WAKO (Japan) and paeoniﬂorin was from Sigma (St. Louis,
MO). The HPLC-grade acetonitrile was obtained from Mal-
linckrodt (KY, USA), and deionized water was prepared
from a Barnstead water puriﬁcation system (Dubuque,
IA, USA). Alexa568-phalloidin and Hoechst 33258 were
from Invitrogen Co. Antibodies against VEGF receptor-3,
phospho-FAK (Y397), and Rac-1 were obtained from San-
ta Cruz Biotechnology Inc. Actin, immobilon Western, and
secondary antibodies were purchased from Millipore Co.
EDTA-free protease inhibitor cocktail was from Roche Diag-
nostics.
2.3. Cell Line and Culture. Renal cell carcinoma cell line
786O was obtained from ATCC and maintained with Dul-
becco’s Modiﬁed Eagle Medium containing 10% fetal bovine
serum, 2mM L-glutamine, 0.1mM nonessential amino
acids, and 10U/mL penicillin/streptomycin at 37◦Ci na5 %
CO2 humidiﬁed incubator.
2.4. Cell Proliferation Assay. 786O cells (7 × 102 cells/well)
were seeded into 96-well plates overnight and treated with
various concentrations of PS-A for 1–3 days. At the end
of treatment, the cells were incubated with 100μLo ff r e s h
medium containing 0.5mg/mL of 3-[4,5-dimethyl-2-thia-
zolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma).
After incubation for 4h, 100μL of 10% SDS/0.1M HCl was
added into well to dissolve the crystal. Absorbance of the
reaction products was measured at 590nm with a reference
wavelength 650nm.
2.5. Transwell Migration and Invasion Assay. After serum
starvation for 24h, 786O cells (2.5 × 104 cells) were resus-
pended in 300μL of serum-free medium containing various
concentrations of PS-A and then seeded into transwell
chambers with or without 40μLo fm a t r i g e l( 1m g / m L ,B D )
for invasion or migration assay, respectively. The chambers
were put into wells of 24-well plates and incubated with
1mL of complete medium with 10% FBS at 37◦Cf o r6 h .
Cells on the bottom side of the membrane were ﬁxed by
1% formaldehyde/PBS for 10min and stained with 0.2%
crystal violet for 60min. The migrated or invaded cells were
counted using an inverted contrast light microscope under
100x magniﬁcation.
2.6. Wound-Healing Assay. 786O cells were full conﬂuent in
12-well plates at the time of scrapping. Cells were wound
with P200 pipette tips and washed with PBS. Cells were then
incubated with fresh complete medium containing various
concentrations of PS-A. Photographs were taken at the same
position of the wound at 0 and 6h after scrapping.
2.7. Mouse Xenograft Model. Four-week-old female NOD-
SCIDmicewereobtained fromtheNationalLaboratoryAni-
mal Center. Approval for animal experiments was obtainedEvidence-Based Complementary and Alternative Medicine 3
from the Institutional Animal Care and Use Committee of
College of Medicine, National Taiwan University. For tumor
growthexperiments,786Ocells(2 ×106 cells)wereinoculat-
ed subcutaneously into the ﬂank of mice. Two days after in-
jection, mice were randomly divided into two groups (4
mice per group) and oral-administrated with water or PS-
A (0.29g/kg) ﬁve times per week. Tumor size was measured
with calipers every ﬁve day, and mice were sacriﬁced after 45
days. Tumor volume was evaluated using the formula: 0.52 ×
(width)2× length [25]. For tumor metastasis experiments,
786O cells (2 × 106 cells) were intravenously inoculated to
the lateral tail vein. Two days after injection, mice were ran-
domly divided into two groups (4 mice per group), and oral-
administrated with water or PS-A (0.29g/kg) ﬁve times per
w e e ka n dw e i g h t e de v e r yﬁ v ed a y .M i c ew e r es a c r i ﬁ c e da f t e r
48 days, and the lungs were excised and ﬁxed by 10% of
formaldehyde. The metastatic nodules of lungs were counted
for evaluation of approximating tumor content of lungs.
2.8. Western Blot Analysis. After serum starvation for 24h,
786Ocells(106 cells)weretreatedwithorwithout0.3mg/mL
of PS for 24h and then lysed by RIPA buﬀer (50mM Tris-
HCl pH 7.5, 150mM NaCl, 5mM EDTA, 1% Triton X-
100, 0.1% SDS, and Roche protease inhibitor cocktail). Fifty
μg of protein was resolved on 10% SDS-polyacrylamide gel
and transferred to polyvinylidene ﬂuoride membranes (Mil-
lipore, Bedford, MA). The membrane was incubated with
primary speciﬁc antibodies to VEGFR-3, phosphor-FAK, or
actin, followed by horseradish peroxidase-conjugated sec-
ondary antibodies (Chemicon International, Temecula, CA).
Signals were visualized using enhanced chemiluminescence
detection reagent from Millipore. Band intensities were ob-
tained using a UVP BioImaging System (UVP Inc., Upland,
CA).
2.9. Rac-1 Activity Assay. 786O cells were starved for 24h,
treated with or without 0.3mg/mL of PS-A for 12h, and
lysed by lysis buﬀer (50mM Tris pH 7.6, 150mM NaCl, 1%
Triton X-100, 0.5mM MgCl2, and Roche protease inhibitor
cocktail). 800μg of total lysate was mixed to glutathione
beads coupled with the bacterially produced Rac binding
domain of Pak (PBD)-GST fusion protein (a gift from Dr.
Zee-Fen Chang) by head-to-head rotation at 4◦C overnight.
After centrifugation at 14,000rpm for 2min, the GST-PBD
b e a d sw e r ew a s h e dﬁ v et i m e sw i t h5 0 0μLo fl y s i sb u ﬀer by
rotating for 10min and then boiled with SDS sample buﬀer
(125mM Tris-HCl, pH 6.8, 4% SDS, 5%β-mercaptoethanol,
30% glycerol, and 0.2% bromophenol blue dye) for 10min
to release GTP-bound Rac-1 proteins and then subjected to
western blot analysis.
2.10. Immunoﬂuorescence Analysis. 786O cells were seeded
on 22 × 22mm cover slides and then treated with fresh med-
iumcontainingvariousconcentrationsofPS-Afor12h.Cells
were washed by PBS and ﬁxed using 4% formaldehyde/PBS
for 10min. After being permeabilized by 0.25% Triton X-
100/PBS, cells were stained by Alexa568-phalloidin and
Hoechst 33258 for 15min. The cover slides were mounted
Table 1: Values of IC50 growth and IC50 migration of Chinese herb ex-
tracts at 24h for 786O cells.
IC50 growth
(mg/mL)
IC50 migration
(mg/mL)
IC50 growth/
IC50 migration
Paeonia suﬀruticosa 1.5 0.3 5.0
Trichosanthes kirilowii 30.0 6.2 4.8
San jhong kuei jian tang 22.4 9.8 2.3
Taraxacum monogolicum 3.8 2.3 1.7
Kalimeris indica 4.8 3.7 1.3
Platycodi radix 2.1 1.7 1.2
Abrus precatorius 5.9 — —
Catharanthus roseus 25.1 — —
Andrographis paniculata ———
Curcuma zedoaria ———
in 80% glycerol and sealed with nail polish. The images were
analyzed with a Leica TCS SP5 Spectral Confocal System.
2.11. Preparation of F- and G-Actin Fractions. F-actin was
separated from G-actin as described previously with some
modiﬁcations [26]. Brieﬂy, 786O cells (2 × 105 cells) were
treated with 0.3mg/mL of PS-A for 12h and then incubated
with 200μL actin stabilizing buﬀer (1% Triton X-100,
1μg/mL phalloidin and Roche protease inhibitor cocktail)
at room temperature for 5min. The lysate was collected,
and F-actin was separated from G-actin by centrifuging at
100,000×ga t3 7 ◦C for 1h. The supernatant was G-actin-
containing fraction, and the pellet containing F-actin was
washedbyPBStwiceanddissolvedby200μLofactindissolv-
ing buﬀer (1% Triton X-100, 2% SDS and protease inhibitor
cocktail) on ice for 1h. The F-actin and G-actin fractions
werethenanalyzedbywesternblotting.Theintensityofband
in each lane was determined with a Gel-Pro analyzer (Media
Cybernetics, GA, USA).
3. Results
3.1. Aqueous Extracts of Paeonia suﬀruticosa Suppresses RCC
Cell Migration. To identify active Chinese herb medicines to
s u p p r e s sm e t a s t a t i cp r o c e s so fR C C ,a q u e o u se x t r a c t so ft e n
kinds of Chinese herb medicines were prepared for treating
786O cells, the aggressive RCC cell line. The results of
MTT assay and transwell migration assay revealed that aque-
ous extracts of Paeonia suﬀruticosa (PS-A) showed a
higher inhibitory eﬀect on cancer cell growth (IC50 growth =
1.5mg/mL) and a higher ratio between inhibitory eﬀects
on cancer cell proliferation and migration in 786O cells
(IC50 growth/IC50 migration =5.0),whereastheothernineCHMs
showed lower or no inhibitory eﬀects on cell migration ac-
tivity (Table 1, Figures 2(a) and 2(b)). Additionally, cell mo-
bility and invasion activities of 786O cells were strongly
suppressed by the treatment of PS-A (Figures 2(c) and
2(d)). These results suggest that PS-A has strong anticancer
activities to RCC cells.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Anticancer eﬀects of PS-A on RCC cells. (a) 7 × 102 of 786O cells were treated with various concentrations of PS-A for 1, 2, and
3 days. The rate of cell proliferation was measured by MTT assay. The data are represented as the means ± SD (n = 5). (b) 2.5 × 104 of
786O cells were seeded in transwell chambers and incubated in serum-free medium containing 0, 0.3, and 0.6mg/mL of PS-A for 12h. The
migratedcellsonthebottomoftranswellchamberswereﬁxedandthenstained.Themigratoryactivitywasdeterminedbycountingmigrated
cells in three microscopic ﬁelds. The data are represented as the means ± SD (n = 3). ∗P<0.05; ∗∗P<0.001 compared with untreated
cells. (c) Fully conﬂuent 786O cells were scrapped by P200 pipette tips and then treated with 0, 0.3, and 0.6mg/mL of PS-A. Images were
taken at 0 and 6h after scrapping under 100x magniﬁcation. (d) 2.5 × 104 of 786O cells were seeded in matrigel-coated chambers and then
incubated in serum-free medium containing 0, 0.3, and 0.6mg/mL of PS-A for 18h. The invaded cells were ﬁxed and then stained. The
invasive activity was determined by counting invaded cells in three microscopic ﬁelds. The data are represented as the means ± SD (n = 3).
∗P<0.05; ∗∗P<0.001 compared with untreated cells.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Inhibition of PS-A on tumor growth and metastasis in vivo.( a )2× 106 of 786O cells were inoculated s.c. into the ﬂank of NOD-
SCID mice (n = 4). Mice were oral-administrated with water or PS-A (0.29g/kg) for ﬁve days per week. After 45 days, mice were sacriﬁced
and tumors were excised. The weights of tumors are represented as the means ± SD (n = 4). ∗P<0.05 compared with control. (b) 2 × 106
of 786O cells were inoculated i.v. into the tail vein of NOD-SCID mice (n = 4). Mice were oral-administrated with water or PS (0.29g/kg)
for ﬁve days per week. After 48 days, mice were sacriﬁced, and number of metastatic nodules of lung was counted. The number of nodules is
represented as the means ± SD (n = 4). ∗P<0.05 compared with control. (c) Body weight of mice oral-administrated with water or PS-A
(0.29g/kg) for ﬁve days per week. Data are represented as the means ± SD (n = 4).
3.2. PS-A Inhibits Tumor Growth and Metastasis In Vivo. To
investigate the eﬀects of PS-A on tumor growth in vivo,2
× 106 of 786O cells were injected subcutaneously into the
hind limb of NOD-SCID mice, and then the mice were oral-
administrated with water or PS-A (0.29g/kg) ﬁve days per
week for 45 days. As shown in Figure 3(a), tumor weight of
PS-A-treated mice was remarkably lower than that of control
group (234.8mg versus 437.5mg, resp.; P<0.05). Moreover,
2 × 106 of 786O cells were i.v. injected into lateral tail vein of
NOD-SCID mice to examine the eﬀects of PS-A (0.29g/kg)
on the metastatic activity of cancer cells. After 48 days,
the number of pulmonary nodules in PS-treated mice was
signiﬁcantly lower than that of untreated group (10 ± 1.2
versus 18.0 ± 3.3nodules/lung, resp.; P<0.01; Figure 3(b)).
Additionally, feeding of PS-A (0.29g/kg) for 48 days had
no signiﬁcant eﬀect on body weight of mice, suggesting
that PS-A showed a very low toxicity to NOD-SCID mice
(Figure 3(c)).TheseresultsindicatethatPS-Ainhibitstumor
growth and pulmonary metastasis of RCC cells signiﬁcantly.
3.3. PS-A Represses VEGFR-3/FAK/Rac-1 Signaling Pathway.
To explore the mechanism for the anticancer activities of
PS-A, we examined the eﬀect of PS-A on VEGFRs, which
play an important role in tumor cell growth and metastasis
[27]. The results revealed that the expression of VEGFR-
3 was markedly inhibited by treating 786O cells with PS-A6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Suppression of VEGFR-3/FAK/Rac-1 signaling by PS-A. (a) After serum starvation for 24h, 786O cells were treated with or
without 0.3mg/mL of PS-A for 24h, and the lysates were analyzed by Western blot analysis to detect the expression levels of VEGFR-3 and
the phosphorylated status of FAK. Actin was used as the loading control. The intensities of bands were quantitated and normalized to actin
levels.(b)Afterserumstarvationfor24h,786Ocellsweretreatedwithorwithout0.3mg/mLofPS-Afor12h,andthelysateswereincubated
with GST-PBD beads to examine the levels of GTP-bound Rac-1 (upper) .T h el e v e l so ft o t a lR a c - 1a n da c t i ni nt o t a ll y s a t e sw e r ea n a l y z e db y
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(Figure 4(a)). It has been shown that VEGFRs are involved
in the activation of FAK [28]. Therefore, we examined the
phosphorylatedstatusofFAKinRCCcellstreatedwithPS-A.
The results revealed that the phosphorylation of FAK in PS-
A-treated 786O cells was remarkably reduced as compared
with that of control cells (Figure 4(a)). Recent reports have
shown that phosphorylated FAK is capable of promoting the
activation of Rac-1 [29]. To investigate the eﬀects of PS-
A on activation of Rac-1, GST-PBD fusion proteins were
puriﬁed to perform pull-down assay. GTP-bound Rac-1 of
786O cells was signiﬁcantly decreased by treating with PS-
A as demonstrated by pull-down assay, revealing that PS-A
reduces the activation of Rac-1 (Figure 4(b)). These results
indicate that PS-A suppresses cancer cell migration by inhib-
iting VEGFR-3/FAK/Rac-1 signaling pathway.
3.4. PS-A Reduces the Formation of Actin Filaments of RCC
Cells. Recent studies demonstrated that Rac-1 has been
reported to be a modulator of cytoskeletal dynamics to aﬀect
cell migration [30], and the dynamic change of actin cyto-
skeleton plays an essential role in cell mobility and migration
[31]. Therefore, the eﬀects of PS-A on the formation of
actin ﬁlaments were studied by staining with phalloidin.
The results revealed that PS-A markedly decreased actin
ﬁlamentformationasshownbyconfocalmicroscopeanalysis
(Figure 5(a)). The ratio of F-actin to G-actin in PS-A-treated
786O cells was signiﬁcantly reduced as compared with that
of control cells (Figure 5(b)). These results indicate that PS-
A disrupts the polymerization of actin ﬁlaments to inhibit
the migration of RCC cells.
4. Discussion
Many studies demonstrated the anticancer activities of
Chinese herb medicines in leukemia, colorectal carcinoma,
gastric cancer, breast cancer, and prostate cancer [32–36].
Therefore, Chinese herb medicines have been considered as
the alternative medicine to treat many tumors which are re-
sistant to traditional cancer therapies. In this study, ten kinds
of potential Chinese herb medicines were screened and the
a q u e o u se x t r a c t so fPaeonia suﬀruticosa exhibited a high-
er antiproliferation activity to RCC cells. Previous studies
showed that Paeonia suﬀruticosa inhibits proliferation in hu-
man malignancies including liver cancer [7, 13], esophageal
cancer [11, 37], and lung cancer cell lines [14]. Therefore,
Paeonia suﬀruticosa could be considered as a potential adju-
vant therapy to enhance the eﬃcacy of chemotherapy for pa-
tients with aggressive RCC.
VEGFR-3 belongs to the family of receptor tyrosine
kinaseandisabletoactivateFAK/Rac-1pathway[28,38,39].
Garces et al. have demonstrated that the NH2-terminus of
VEGFR-3isassociatedwiththeCOOHterminusofFAK,and
disruption of VEGFR3/FAK interaction results in the dis-
sociation of FAK from the focal adhesions [28]. The expres-
sionofVEGFR-3hasbeenfoundtobeupregulatedinvarious
human malignancies, including leukemia, breast cancer, col-
orectal cancer, prostate cancer, renal cell carcinoma, and he-
patocellularcarcinoma[38,40].ExpressionlevelsofVEGFR-
3 are correlated with portal vein invasion, tumor recurrence,
and shorter disease-free survival in HCC patients [41, 42]. It
has been shown that the activation of VEGFR-3 participates
in cell proliferation, migration, and survival [43]. This study
demonstrated that PS-A at the concentration of IC50 migration
markedly reduces VEGFR-3 expression and inhibits the acti-
vation of VEGFR-3 signaling, indicating that PS-A may have
the potential to prevent the progression of human malignan-
cies.
The invasion of cancer cells into adjacent tissues is a
critical step in the process of tumor metastasis [44]. Devel-
oping of the migratory capacity plays an essential role inEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Disruption of actin ﬁlament formation by PS-A in RCC cells. (a) 2 × 105 of 786O cells were treated with 0, 0.3, and 0.6mg/mL
of PS-A for 12h. After ﬁxation, cells were stained with Alexa568-phalloidin (red) and Hoechst 33258 (blue). Fluorescent images were taken
with a Leica TCS SP5 Spectral Confocal System. Bars, 20μm. (b) 2 × 105 of 786O cells were treated with or without 0.3mg/mL of PS-A,
and the fractions containing F- or G-actin were separated and then subjected to Western blotting using actin antibody. The intensities of
bands were quantitated, and the ratio of F-actin to G-actin was calculated. The data are represented as the means ± SD (n = 3). ∗P<0.05
compared with untreated cells.
cancercellinvasiveness[31].Inthisinvestigation,wedemon-
strate that PS-A exhibits strong inhibitory eﬀects on the mi-
gration, invasion, and metastasis of RCC cells. It might
be achieved by disrupting the polymerization of actin ﬁla-
ments, which is tightly regulated during cell migration [45].
Previous studies suggested that the motility of cancer cells
is mainly managed by the Rho family of GTPases [46]. Our
results showed that the activity of Rac-1, one member of the
Rho family, was suppressed by PS-A in RCC cells, indicating
the potential mechanism for the inhibitory eﬀects of PS-A to
cancer cell migration.
In conclusion, this research demonstrates that PS-A is
able to prohibit tumor growth and metastasis through dis-
rupting the formation of actin ﬁlament and impairing the
signaling pathway of VEGFR-3. The present results elucidate
anticancer mechanism of PS-A and suggest that PS-A is a
potential therapeutic or adjuvant strategy for the treatment
of RCC patients.
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